Literature DB >> 26984086

Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis.

Atsushi Miyamoto1, Nasa Morokawa, Yui Takahashi, Kazumasa Ogawa, Makiko Takeyasu, Kyoko Murase, Shigeo Hanada, Hironori Uruga, Sayaka Mochizuki, Hisashi Takaya, Atsuko Kurosaki, Kazuma Kishi.   

Abstract

A man in his mid-60's with idiopathic pulmonary fibrosis and hepatitis B-related liver cirrhosis developed exertional dyspnea and a dry cough lasting for three months. High-resolution computed tomography (HRCT) showed increasing bilateral ground-glass opacity superimposed on the usual interstitial pneumonia pattern. Six months after starting pirfenidone therapy, the partial pressure of arterial oxygen at rest increased from 81 to 101 torr, the predicted forced vital capacity (FVC) value increased from 75% to 94% and the ground-glass opacity on HRCT improved. The FVC value was subsequently maintained near or above baseline for 43 months. We concluded that our patient was a super-responder to pirfenidone therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26984086     DOI: 10.2169/internalmedicine.55.5259

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

Review 1.  Anti-TNFα therapy in inflammatory lung diseases.

Authors:  Rama Malaviya; Jeffrey D Laskin; Debra L Laskin
Journal:  Pharmacol Ther       Date:  2017-06-19       Impact factor: 12.310

2.  Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis.

Authors:  Chunmei Li; Rui Han; Le Kang; Jianping Wang; Yonglin Gao; Yanshen Li; Jie He; Jingwei Tian
Journal:  Sci Rep       Date:  2017-01-16       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.